Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.
Merck and Moderna’s personalized mRNA vaccine with Keytruda reduced melanoma recurrence in a 1,137-patient Phase 3 trial—the first late-stage win for an mRNA cancer vaccine.
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.